Atara Biotherapeutics Files Biologics License Application for Tab-cel® to Treat EBV Positive Post-Transplant Lymphoproliferative Disease with the FDA.

New Phase 2a trial data shows Endeavor BioMedicinesa’ ENV-101 enhanced lung performance and reversed critical indicators of lung fibrosis in idiopathic pulmonary fibrosis patients.

Experimental Seladelpar Shows Notable Advancements in Liver Disease and Alleviates Itching in Primary Biliary Cholangitis.

The SUPERNOVA Phase III trial for the long-acting antibody sipavibart successfully met its primary goals in preventing COVID-19 among immunocompromised patients.

Recludix Pharma Shares Data Showing Oral STAT3 Inhibitors Offer Unique Efficacy and Safety in Th17-Driven Skin Inflammation Preclinical Models during Oral Session at SID Annual Meeting.

Apogee Starts Phase 2 Trial of APG777 in Atopic Dermatitis with First Patient Dosed. APG777 is a new long-acting IL-13 inhibitor for treating Atopic Dermatitis and various inflammatory conditions.

Voyager Therapeutics, Inc. revealed that the initial subjects have been administered doses in a Phase 1a single ascending dose study of VY-TAU01.

Tourmaline Bio Begins Clinical Trials for TOUR006 in Cardiovascular Disease; First Patient Treated in Phase 2 TRANQUILITY Study.

CASI Pharmaceuticals Gets FDA Approval For Investigational New Drug CID-103 In Treating Immune Thrombocytopenia (ITP).

Ractigen Therapeutics Gains NMPA Clearance to Begin Phase 1 Trials of RAG-17 in Chinese SOD1-ALS Patients.

With Weekly Dosing, Insulin Efsitora Alfa Achieves A1C Reduction and Matches Safety of Daily Insulin.

Biopharmaceutical firm Iterion Therapeutics has initiated a Phase 1b/2a clinical trial for its lead drug candidate, tegavivint, which is designed to inhibit Transducin beta-like protein 1 (TBL1).